Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SGLT 2 Inhibitors”

382 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 382 results

Post-approval studies (Phase 4)Looking for participantsNCT07323524
What this trial is testing

Dapagliflozin in Active Lupus Nephritis

Who this might be right for
Lupus Nephritis (LN)
Brigham and Women's Hospital 33
Not applicableStudy completedNCT05890131
What this trial is testing

Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

Who this might be right for
Heart Failure
Morten Schou 5,996
Post-approval studies (Phase 4)Study completedNCT04642261
What this trial is testing

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Who this might be right for
Non-alcoholic Fatty Liver Disease
The University of Hong Kong 98
Testing effectiveness (Phase 2)Study completedNCT03922750
What this trial is testing

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Who this might be right for
Diabetes Mellitus, Type 2
Novo Nordisk A/S 154
Post-approval studies (Phase 4)Study completedNCT03982381
What this trial is testing

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
Uppsala University 2,067
Not applicableUnknownNCT03917758
What this trial is testing

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Who this might be right for
Diabetes Mellitus, Type 2Arterial HypertensionBody Weight Changes
University of Turin, Italy 30
Not applicableLooking for participantsNCT06271200
What this trial is testing

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Who this might be right for
Metabolic Syndrome
National Health Research Institutes, Taiwan 200
Post-approval studies (Phase 4)Looking for participantsNCT07292909
What this trial is testing

Effect of Empagliflozin on Inflammation

Who this might be right for
CAD - Coronary Artery DiseaseInflamationPCI+1 more
Hotel Dieu de France Hospital 100
Not applicableNot Yet RecruitingNCT06739486
What this trial is testing

Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

Who this might be right for
Non Alcholic Fatty Liver DiseaseHepatic SteatosisHepatic Fibrosis+1 more
Assiut University 100
Not applicableStudy completedNCT06288529
What this trial is testing

EFFECT SGLT2 INHIBITORS ON CONTRAST MEDIUM INDUCED ACUTE KIDNEY INJURY

Who this might be right for
Chronic Kidney DiseasesType2diabetes
University of Health Sciences Balikesir Hospital Eduation and Research 975
Post-approval studies (Phase 4)Study completedNCT06268977
What this trial is testing

Adding SGLt2 Inhibitors to Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
Assiut University 482
Large-scale testing (Phase 3)Study completedNCT03087773
What this trial is testing

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Who this might be right for
Acute Myocardial Infarction
Medical University of Graz 476
Not applicableEnded earlyNCT05341388
What this trial is testing

The Effect of SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Patients With Type 2 Diabetes

Who this might be right for
Type2 DiabetesCognitive Impairment
Goztepe Training and Research Hospital 25
Not applicableStudy completedNCT05640180
What this trial is testing

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Who this might be right for
Chronic Kidney DiseaseType 2 Diabetes
Bayer 17,847
Post-approval studies (Phase 4)Ended earlyNCT05737186
What this trial is testing

SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

Who this might be right for
Heart Failure With Reduced Ejection FractionRenal Insufficiency, Chronic
Peking University People's Hospital 11
Testing effectiveness (Phase 2)Looking for participantsNCT07336797
What this trial is testing

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Who this might be right for
Metabolic SyndromeObesity & OverweightHIV (Human Immunodeficiency Virus)
Abdelrahman Mahmoud 66
Post-approval studies (Phase 4)Active Not RecruitingNCT07325435
What this trial is testing

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

Who this might be right for
Type 2 Diabetes (T2DM)
MaryAnn Banerji 60
Testing effectiveness (Phase 2)Study completedNCT03951805
What this trial is testing

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Who this might be right for
Diabetes Mellitus, Type 2
Novo Nordisk A/S 205
Post-approval studies (Phase 4)Active Not RecruitingNCT03878459
What this trial is testing

Dapagliflozin Plus Pioglitazone in T1DM

Who this might be right for
Type 1 Diabetes Mellitus
The University of Texas Health Science Center at San Antonio 120
Post-approval studies (Phase 4)Study completedNCT03267576
What this trial is testing

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Who this might be right for
Diabetes Mellitus, Type 2
Janssen Research & Development, LLC 64
Next Page